[en] It is well known that the optimal management of diabetes mellitus requires the use of various insulin formulations with complementary pharmacokinetics, in order to better mimic physiological (basal and postprandial) insulin secretion. Recent advances led to the production of insulin analogues thanks to the substitution of specific amino acids. Pharmacokinetics is improved, without affecting pharmacodynamics or increasing side-effects. These new insulin forms concern both so-called ultra-short insulin analogues and long-acting insulin analogues (basal insulin). Even if they are not able to dramatically lower glycated haemoglobin levels, these new insulins significantly reduce the risk of hypoglycaemia and offer some practical advantages that could improve the quality of life of diabetic patients.
Precision for document type :
Case briefs/Comments on statutes or statutory instruments
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
PHILIPS, Jean-Christophe ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques
Radermecker, Régis ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
Binder C, Lauritzen T, Faber O, et al. Insulin pharmacokinetics. Diabetes Care 1984;7:188-99.
Hirsch I. Insulin analogs. N Engl J Med 2005;352:174-83.
Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs 2005;65:325-40.
Ciofetta M, Lalli C, Del Sindaco P, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type I diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999;22:795-800.
Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicencer Insulin Lispro Study Group. Diabetes 1997;46:265-70.
Philips J-C, Radermecker RP. L'insulinothérapie dans le diabète de type I. Rev Med Liège 2005;60:322-8.
Philips J-C, Scheen AJ. L'insulinothérapie dans le diabète de type 2. Rev Med Liège 2005;60:419-23.
Vignati L, Anderson JH Jr, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther 1997;19:408-21.
Colombel A, Murat A, Krempf M, et al. Improvement of blood glucose control in Type I diabetic patients treated with lispro and multiple NPH injections. Diabet Med 1999;16:319-24.
Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: The role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-804.
Brunelle BL, Llewelyn J, Anderson JH Jr, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type I diabetes. Diabetes Care 1998;21:1726-31.
Raskin, P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5.
Riddle M, Rosenstock J, Gerich J, et al. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
Hermansen K, Derezinski T, Kim H, Gall M-A. Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes (Abstract). Diabetologia 2004;47(Suppl. 1):A273-4.
Janka H, Plewe G, Riddle M, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9.
Radermecker RP, Hermans MP, Legrand DA, Scheen AJ. L'insulinothé rapie par pompe externe à perfusion continue d'insuline. Rev Med Liège 2005;60:329-34.
Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: Efficacy, safety, quality of life and cost-effectiveness. Diabetes/Metab Res Rev 2004;20:178-88.
